Cinctive Capital Management LP Purchases New Stake in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

Cinctive Capital Management LP acquired a new position in shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 92,628 shares of the company’s stock, valued at approximately $2,246,000. Cinctive Capital Management LP owned 0.07% of Centessa Pharmaceuticals at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the business. Campbell & CO Investment Adviser LLC purchased a new stake in shares of Centessa Pharmaceuticals during the 2nd quarter worth $218,000. DNB Asset Management AS purchased a new position in shares of Centessa Pharmaceuticals in the 3rd quarter valued at about $218,000. China Universal Asset Management Co. Ltd. increased its holdings in shares of Centessa Pharmaceuticals by 4.8% in the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 19,181 shares of the company’s stock valued at $252,000 after purchasing an additional 870 shares in the last quarter. GSA Capital Partners LLP acquired a new stake in shares of Centessa Pharmaceuticals in the third quarter valued at about $455,000. Finally, BNP Paribas Financial Markets lifted its stake in shares of Centessa Pharmaceuticals by 3,028.1% in the second quarter. BNP Paribas Financial Markets now owns 34,972 shares of the company’s stock valued at $460,000 after purchasing an additional 33,854 shares during the period. Hedge funds and other institutional investors own 82.01% of the company’s stock.

Insiders Place Their Bets

In related news, insider Iqbal J. Hussain sold 38,951 shares of the stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $25.15, for a total transaction of $979,617.65. Following the sale, the insider owned 57,645 shares of the company’s stock, valued at $1,449,771.75. This trade represents a 40.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Gregory M. Weinhoff sold 73,196 shares of Centessa Pharmaceuticals stock in a transaction dated Friday, March 13th. The stock was sold at an average price of $26.33, for a total value of $1,927,250.68. Following the sale, the insider owned 65,925 shares of the company’s stock, valued at approximately $1,735,805.25. This represents a 52.61% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 233,186 shares of company stock valued at $6,082,890. Corporate insiders own 7.09% of the company’s stock.

Analyst Ratings Changes

CNTA has been the topic of several recent analyst reports. Piper Sandler restated an “overweight” rating on shares of Centessa Pharmaceuticals in a research report on Friday, January 16th. Wolfe Research initiated coverage on shares of Centessa Pharmaceuticals in a research report on Tuesday, February 24th. They set an “outperform” rating and a $40.00 price target for the company. TD Cowen reissued a “buy” rating on shares of Centessa Pharmaceuticals in a research note on Wednesday, January 14th. Guggenheim upped their price target on Centessa Pharmaceuticals from $28.00 to $43.00 and gave the stock a “buy” rating in a report on Tuesday, November 18th. Finally, B. Riley Financial raised their price objective on Centessa Pharmaceuticals from $33.00 to $42.00 and gave the company a “buy” rating in a research note on Monday, December 1st. Two research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $39.80.

Centessa Pharmaceuticals Trading Up 7.4%

Shares of Centessa Pharmaceuticals stock opened at $28.29 on Tuesday. Centessa Pharmaceuticals PLC Sponsored ADR has a 1 year low of $9.60 and a 1 year high of $30.58. The company has a debt-to-equity ratio of 0.36, a current ratio of 10.56 and a quick ratio of 10.57. The business has a 50 day moving average price of $24.80 and a 200 day moving average price of $24.43. The company has a market capitalization of $4.13 billion, a P/E ratio of -15.46 and a beta of 1.54.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.